Innate Pharma (XPAR:IPH) Days Payable: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:IPH Innate Pharma SA XPAR:IPH
32 GF Score
Price €1.58
GF Value €0.13
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Innate Pharma Days Payable?

Innate Pharma's average Accounts Payable for the six months ended in Jun. 2026 was €6.45 Mil. Innate Pharma's Cost of Goods Sold for the six months ended in Jun. 2026 was € Mil.

The historical rank and industry rank for Innate Pharma's Days Payable or its related term are showing as below:

During the past 13 years, Innate Pharma's highest Days Payable was 26289.75. The lowest was 151.87. And the median was 1993.63.

XPAR:IPH's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 111.24
* Ranked among companies with meaningful Days Payable only.

Innate Pharma's Days Payable stayed the same from Jun. 2025 () to Jun. 2026 ().

Innate Pharma Days Payable Historical Data

* Premium members only.

The historical data trend for Innate Pharma's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innate Pharma Days Payable Chart

Innate Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only

Innate Pharma Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only

XPAR:IPH vs VRTX, REGN, MRNA: Days Payable Comparison

For the Biotechnology subindustry, Innate Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innate Pharma Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's Days Payable distribution charts can be found below:

* The bar in red indicates where Innate Pharma's Days Payable falls into.


XPAR:IPH
32GF Score
Innate Pharma SA XPAR:IPH
Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Innate Pharma Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Innate Pharma's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

Days Payable (A: Dec. 2025 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2024 ) + Accounts Payable (A: Dec. 2025 )) / count ) / Cost of Goods Sold (A: Dec. 2025 )*Days in Period
=( (7.923 + 7.475) / 2 ) / *365
=7.699 / *365
=N/A

Innate Pharma's Days Payable for the quarter that ended in Jun. 2026 is calculated as:

Days Payable (Q: Jun. 2026 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Dec. 2025 ) + Accounts Payable (Q: Jun. 2026 )) / count ) / Cost of Goods Sold (Q: Jun. 2026 )*Days in Period
=( (7.475 + 5.43) / 2 ) / *365 / 2
=6.4525 / *365 / 2
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Innate Pharma (XPAR:IPH) Overvalued in 2026?

Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued. The current stock price of €1.58 is trading 1115.4% above its estimated GF Value™ of €0.13. GuruFocus considers Innate Pharma to be Significantly Overvalued.

Key valuation signals for XPAR:IPH:

  • Days Payable:
  • GF Value™: €0.13 vs. price of €1.58 (1115.4% above fair value)
  • GF Score™: 32/100 with 6 warning signs

No single metric tells the full story. See the XPAR:IPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Innate Pharma Business Description

Address 117, Avenue de Luminy, Marseille, FRA, 13009
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
32GF Score

Get the complete analysis for XPAR:IPH

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.58
Price
€0.13
GF Value